Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy

* This study aims to investigate whether Coenzyme Q10 supplementation can reduce chemotherapy-induced peripheral neuropathy, fatigue, and pain in women with newly diagnosed breast cancer receiving paclitaxel treatment. The study will also examine the effects of Coenzyme Q10 on biomarkers associated with nerve damage. The main questions it seeks to answer are: * Does Coenzyme Q10 improve patients' quality of life by reducing neuropathy, fatigue, and pain during chemotherapy? * How does Coenzyme Q10 affect serum levels of nerve growth factor, neurofilament light chain, malondialdehyde, and osteopontin during treatment? * Participants will: Receive either Coenzyme Q10 along with standard weekly paclitaxel chemotherapy or paclitaxel alone for twelve weeks. * Complete questionnaires on neuropathy, fatigue, and pain at the end of each chemotherapy cycle. * Provide blood samples at the beginning and end of the study to measure biomarkers of nerve injury.

NCT Number	NCT07307911
Lead Sponsor	Damanhour University
Conditions	Breast Cancer
Enrollment	50 participants
Start Date	2025-11-10
Primary Completion	2026-02-10 (estimated)
Study Completion	2026-02-10 (estimated)
Updated on ClinicalTrials.gov	2026-04-08